Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our range of services cover phases I, II and III ECG safety studies for cardiovascular and non-cardiovascular compounds.

Many "normal" healthy volunteers will have abnormal ECGs or have abnormal ECGs which they are aware of. These abnormal ECGs may have a big impact on the development of a new chemical entity if the data obtained is not scrutinised properly at an early stage.

Early signal detection and full follow up by Richmond Pharmacology's cardiology team is essential to ensure that the digital ECG data obtained from an early phase trial is analysed and reported appropriately. Richmond Pharmacology has the capacity to undertake and subsequently analyse several cardiological assessments to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Analysis services include rest and exercise ECG analysis, detailed digital QT analysis, entry criteria validation, cardiac event classification and Holter provision, analysis and review. The assessments are performed using Richmond's bespoke and integrated MUSE setup.

We ensure rapid and reliable digital ECG data is obtained to support the “go” or “no-go” decisions during your early phase trial.

Get in touch today

Latest news

Richmond Pharmacology appoints Sandra Johnson as Director of Commercial Project Management

September 19, 2022
We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management
Read more

How telemonitoring can revolutionise the way we treat patients – Tom York

November 17, 2022
Richmond Pharmacology always searches for the most innovative processes to improve clinical trials and the patients’ experiences and treatments.
Read more

Events

JPW2022 (Japan Basic and Clinical Pharmacology Week 2022)

30 November – 3 December 2022
This event will be the 96th Annual Meeting of the Japanese Pharmacological Society and the 43rd Annual Meeting of the Japanese Society of Clinical Pharmacology. 
View event